Related Experiment Video
Updated: Mar 2, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Immune Checkpoint in Glioblastoma: Promising and Challenging
Jing Huang1,2, Fangkun Liu3, Zhixiong Liu3
1Department of Psychiatry, the Second Xiangya Hospital, Central South UniversityChangsha, China.
Abstract:
Glioblastoma (GBM) is a severe malignant brain cancer with poor overall survival. Conventional intervention remains dismal to prevent recurrence and deterioration of GBM cell. Recent years have witnessed exciting breakthroughs in novel immune strategies, especially checkpoint inhibitors, some of which have become adjuvant setting after standard of care in melanoma. Several clinical trials of checkpoint inhibitors are ongoing in glioblastoma and other brain carcinomas. Plus, synergistic combinations of checkpoint inhibitors with conventional therapy strategies-radiotherapy, temozolomide, bevacizumab, and corticosteroids are now being exploited and applied in clinical settings. This review highlights the recent developments of checkpoints in GBM immunotherapy to provide a brief and comprehensive review of current treatment options. Furthermore, we will discuss challenges remained, such as unique immune system of central nervous system (CNS), immune-related toxicities, synergies, and adverse interactions of combination therapies.
Insights
Novel immune strategies, like checkpoint inhibitors, show promise for glioblastoma (GBM) treatment, offering new hope against this aggressive brain cancer. Research explores combinations with standard therapies to improve outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Glioblastoma (GBM) presents a significant challenge due to poor survival rates and resistance to conventional treatments.
- Emerging immunotherapies, particularly checkpoint inhibitors, are revolutionizing cancer treatment paradigms.
- The central nervous system (CNS) has a unique immune environment that impacts treatment efficacy.
Purpose of the Study:
- To review recent advancements in checkpoint inhibitors for glioblastoma immunotherapy.
- To provide a comprehensive overview of current and emerging treatment options for GBM.
- To discuss the challenges and future directions in GBM immunotherapy.
Main Methods:
- Literature review of recent clinical trials and research on checkpoint inhibitors in glioblastoma.
- Analysis of synergistic combinations of immunotherapies with standard GBM treatments (radiotherapy, temozolomide, bevacizumab, corticosteroids).
- Discussion of the unique immunological aspects of the CNS and their implications for immunotherapy.
Main Results:
- Checkpoint inhibitors are increasingly investigated for glioblastoma, with several clinical trials underway.
- Combination therapies involving checkpoint inhibitors and conventional treatments are being explored for enhanced efficacy.
- Understanding CNS immune dynamics and managing immune-related toxicities are critical for successful immunotherapy.
Conclusions:
- Checkpoint inhibitors represent a promising frontier in glioblastoma treatment, offering potential improvements over existing therapies.
- Synergistic combinations and careful management of toxicities are key to optimizing immunotherapy outcomes in GBM.
- Further research into CNS-specific immune responses is essential for advancing glioblastoma immunotherapy.
